𩺠å
§ç§å°ç§èåç
ð äžé éé»
- 22E: caplacizumab for TTP, voxelotor/crizanlizumab/L-glutamine for SCD, ruxolitinib for PV/MF
- HIF-PHI (roxadustat) for CKD anemia (China/Asia approved)
- Taiwan: thalassemia é« prevalence
ð é²é
TTP Modern Management
- PLEX (plasma exchange) + steroid + caplacizumab (anti-vWF nanobody)
- Rituximab for refractory / relapsed
- ADAMTS13 monitoring
Sickle Cell New Drugs
- Hydroxyurea classic
- Voxelotor (HbS polymerization inhibitor)
- Crizanlizumab (anti-P-selectin Ab)
- L-glutamine
- Gene therapy (Casgevy CRISPR, Lyfgenia lentiviral)
CKD Anemia
- ESA (epoetin, darbepoetin)
- IV iron
- HIF-PHI: roxadustat, daprodustat, vadadustat (oral)
Aplastic Anemia
- Triple immunosuppression: ATG + cyclosporine + eltrombopag (TPO-receptor agonist)
- HSCT for young + severe + matched donor
Polycythemia Vera
- Phlebotomy (Hct < 45%)
- Aspirin
- Hydroxyurea
- Ropeginterferon-α2b (Besremi) â 22E new
- Ruxolitinib for HU-resistant
Pure Red Cell Aplasia
- Parvovirus B19 (in immunocomp)
- Thymoma
- Drugs
ð Pearls (10)
- TTP caplacizumab + PLEX + steroid (HERCULES trial)
- PNH FLAER + CD55/59 flow cytometry diagnostic
- MDS diagnostic: cytogenetics + IPSS-R + WHO
- HU > anti-IL-6 for symptomatic PV pruritus
- Sickle cell hyperbaric / exchange transfusion for stroke prevention
- HIF-PHI: oral CKD anemia, but cardiovascular monitoring
- Eltrombopag for aplastic anemia + ITP
- Aplastic horse-ATG > rabbit-ATG (overall survival)
- CALR + MPL mutations in MPN (PV/ET/MF)
- Voxelotor in SCD: Hgb â but VOC reduction limited
ð Taiwan
- Thalassemia carrier screening æ®å
- G6PD newborn screening
- å¥ä¿ hydroxyurea for SCD/PV
- å¥ä¿ ESA for CKD
- DAA HCV â reduced éšå hepatic anemia
ð å
§å°éé»
- MCV / retic åé¡
- IDA workup + Tx (22E alternate day)
- B12/folate
- Hemolytic anemia åé¡
- TTP / TMA syndromes
- PV / aplastic
- SCD new drugs (22E)
â ïž AI èçš¿ã